# A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

> **NCT04398745** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT04398745
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-09
- **Primary completion:** 2025-04-21
- **Final completion:** 2025-12-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398745, "A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04398745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*